Biaxin, Clarithromycin News

Editor's Choice Main Category: Infectious Diseases / Bacteria / Viruses Also Included In: Immune System / Vaccines Article Date: 14 Jun 2008 - 0:00 PDT A previously healthy man died after inhaling fungal spores ...

The CKS guideline on chest infections [1] reports: "Which antibiotic should I prescribe in a person with community-acquired pneumonia? Amoxicillin is the first-line antibiotic for most people. via NLH Question Answering Service

“IDSA does not say that mortality must be a component of a composite but that there are advantages of having it in there, that if it is a problem one could argue just for morbidity endpoints”

The FDA is re-evaluating the appropriateness of using noninferiority trial designs for anti-infectives used to treat community-acquired pneumonia , which could affect firms like Woodridge, Ill.-based Advanced ... via BioWorld

Michael Moschopulos,* Hansjoerg Hungerbuehler,* Jeannette Guarner, Gillian L. Genrich, and Sherif R. Zaki *Kantonsspital Aarau, Aarau, Switzerland; and Centers for Disease Control and Prevention, Atlanta, ... via Centers for Disease Control and Preve...

My doctor recommended I not take an antibiotic for an infection I developed because I'm nursing and it may harm my baby. via Consumer Reports

Type of Drug H. pylori agent; anti-ulcer drug. How The Drug Works This drug, when combined with other drugs, acts as an anti-infective to help eliminate the bacteria that is responsible for many cases of peptic ... via American Chronicle

Haemophilus influenzae is one of the main aetiological agents of community-acquired respiratory tract infections. via BMC Microbiology

Watson Pharmaceuticals, Inc. has announced it has launched Clarithromycin Extended-Release Tablets, USP in the 500 mg strength. via Medical News

Antimicrob Agents Chemother , Vol. 33, No. 9. , pp. 1531-1534. viktor21614's tags for this article erythromycin erythromycin Abstract There is no effective therapy to treat Mycobacterium avium complex infection ... via CiteULike

Other mycobacteria are mostly saprophytic organisms, living in soil and water, but some of them can cause opportunistic infections. via CiteULike

Samuel D. Sibley † and Joel A. Pedersen *†‡ Environmental Chemistry and Technology Program, and Department of Soil Science, University of Wisconsin, Madison, Wisconsin 53706 Received for ... via Environmental Science & Tech.

Remington Professor of PharmacyPhiladelphia College of Pharmacy, University of the Sciences in Philadelphia, Pa. via Nursing Center

Abstract RATIONALE: Imatinib is an inhibitor of platelet-derived growth factor receptors. via CiteULike

The small pharmaceutical company Advanced Life Sciences has moved a big step closer to providing doctors with a new tool to fight bacteria that have developed resistance to antibiotics. via Forbes

“Cethromycin, a new antibiotic, may be the solution to this important public health problem, as it has demonstrated a broad spectrum of antibacterial activity and an ability to overcome pneumococcal resistance in clinical trials.”

Advanced Life Sciences Holdings, Inc. has announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel ... via Medical News

Clinical data and analyst speculation pushed a few biotech stocks up on Thursday while others fell in light of earnings. via TheStreet.com

“We intend to do further research to determine if cethromycin may have clinical applications for MRSA”

A new antibiotic that Advanced Life Sciences Holdings Inc. hopes to bring to market was shown to be safe and effective in treating pneumonia, the company will report Thursday.

The antibiotic, cethromycin, also has shown in test tube experiments that it can fight MRSA, the so-called superbug staph infection that has caused worries because of its drug resistance.

In trials with patients who had acquired pneumonia in their communities, ALS' cethromycin cured 94 percent, a performance similar to that of Biaxin, the current standard of treatment. Read more

“We are pleased to receive this FDA approval for Clarithromycin for Oral Suspension, it will add depth to our product line of anti-infectives which also includes Clarithromycin tablets”

Business Ranbaxy recieves USFDA approval for anti-bacterial drug New Delhi, Oct. via The Hindu

Ranbaxy received full market approval from the US Food and Drug Admnistration for its anti-infective agent "Clarithromycin" oral suspension, USP . via Pharmaceutical Technology

Ranbaxy Pharmaceuticals Inc. , a wholly owned subsidiary of Ranbaxy Laboratories Limited , announced today that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and ... via Customer Interaction Solutions